Longevity Health Holdings Inc.
XAGE
Get informed when a big investor buys or sells
+ FollowMarket Cap$193.74M
Close$
$0.01
97.8% downside
Current Fair Value
97.8% downsideOvervalued by 97.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $193.74 Million |
|---|---|
| Enterprise Value | $193.82 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.01 |
| Beta | 0.37 |
| Outstanding Shares | 1,899,910 |
Return
| Return on Equity | 99.07% |
|---|---|
| Return on Assets | -415.93% |
| Return on Invested Capital | 79.50% |
Valuation & Multiples
| P/E Ratio | -0.08 |
|---|---|
| PEG | 1.69 |
| Price to Sales | - |
| Price to Book Ratio | -0.06 |
| Enterprise Value to Revenue | 108.03 |
| Enterprise Value to EBIT | -36.35 |
| Enterprise Value to Net Income | -29 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | -0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.74%▼ 0.34% |
|---|---|
| Total Invested | $4,145▼ 26.07% |
| Investors Holding | 1▼ 1.00% |
ESG Score
No data
About Longevity Health Holdings Inc.
15 employees
CEO: Mr. Rajiv Sarman Shukla Longevity Health Holdings Inc focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tib...